Gerda Redl
Corporate Officer/Principal bij igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
Profiel
Gerda Redl is currently the Director-Business Development at igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH.
Previously, she worked as the Chief Commercial Officer at F-Star Biotechnologische Forschungs-.
Und Entwicklungsges MBH from 2006 to 2009.
She also held positions as Principal at Octapharma AG, Baxter Healthcare SA, and Immuno.
Dr. Redl holds a doctorate degree from Vienna University of Economics & Business.
Actieve functies van Gerda Redl
Bedrijven | Functie | Begin |
---|---|---|
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Eerdere bekende functies van Gerda Redl
Bedrijven | Functie | Einde |
---|---|---|
Immuno
Immuno Pharmaceuticals: MajorHealth Technology Part of Baxter International, Inc., Immuno is a German pharmaceutical company. The company is based in Heidelberg, Germany. Immuno was acquired by Baxter International, Inc. on July 01, 1998. | Corporate Officer/Principal | - |
Octapharma AG
Octapharma AG Pharmaceuticals: MajorHealth Technology Octapharma AG develops, produces and sells plasma related products for treatment in coagulation disorders and immune diseases. The firm's products include virus-inactivated plasma for transfusion and fractionation products such as coagulation Factors VIII & IX for the treatment of haemophilia, von Willebrand Factor concentrate, prothrombin complex concentrate and immunoglobulins. Octapharma was founded in 1983 and is headquartered in Lachen, Switzerland. | Corporate Officer/Principal | - |
Baxter Healthcare SA
Baxter Healthcare SA Pharmaceuticals: MajorHealth Technology Baxter Healthcare SA engages in the development, production, and sale of healthcare systems and products. It also acquires and manages participations in pharmaceutical-chemical firms. The company was founded on December 7, 2000 and is headquartered in Glattpark, Switzerland. | Corporate Officer/Principal | - |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Opleiding van Gerda Redl
Vienna University of Economics & Business | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Octapharma AG
Octapharma AG Pharmaceuticals: MajorHealth Technology Octapharma AG develops, produces and sells plasma related products for treatment in coagulation disorders and immune diseases. The firm's products include virus-inactivated plasma for transfusion and fractionation products such as coagulation Factors VIII & IX for the treatment of haemophilia, von Willebrand Factor concentrate, prothrombin complex concentrate and immunoglobulins. Octapharma was founded in 1983 and is headquartered in Lachen, Switzerland. | Health Technology |
Baxter Healthcare SA
Baxter Healthcare SA Pharmaceuticals: MajorHealth Technology Baxter Healthcare SA engages in the development, production, and sale of healthcare systems and products. It also acquires and manages participations in pharmaceutical-chemical firms. The company was founded on December 7, 2000 and is headquartered in Glattpark, Switzerland. | Health Technology |
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Health Technology |
Immuno
Immuno Pharmaceuticals: MajorHealth Technology Part of Baxter International, Inc., Immuno is a German pharmaceutical company. The company is based in Heidelberg, Germany. Immuno was acquired by Baxter International, Inc. on July 01, 1998. | Health Technology |